POLIVY
Clinical safety rating
cautionComprehensive clinical and safety monograph for POLIVY (POLIVY).
Comprehensive clinical and safety monograph for POLIVY (POLIVY).
In combination with bendamustine and rituximab for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies.In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.
| Metabolism | MMAE is primarily metabolized via CYP3A4/5. Less than 10% is metabolized by other CYP isoforms (1A2, 2C9, 2D6, 2E1, 3A4). |
| Excretion | Polivy (polatuzumab vedotin) is eliminated primarily through catabolism into small peptides and amino acids. The antibody-drug conjugate is not significantly excreted renally as intact compound; approximately <1% of the dose is excreted unchanged in urine. The majority of the drug is metabolized and eliminated via biliary/fecal routes, with approximately 80% of the total dose recovered in feces over 3 weeks, primarily as metabolites. |
| Half-life | The terminal elimination half-life of polatuzumab vedotin is approximately 12 days (range 8–20 days) for the antibody-drug conjugate. This supports a dosing interval of every 3 weeks. The half-life may be prolonged in patients with severe hepatic impairment. |
| Protein binding | The conjugate is highly protein-bound (>97%), primarily to plasma proteins such as albumin. The free drug (unconjugated MMAE) is approximately 70–80% bound to albumin. |
| Volume of Distribution | The volume of distribution at steady state is approximately 3.4 L (range 2.8–5.6 L), which corresponds to about 0.049 L/kg (assuming 70 kg). This small Vd indicates limited extravascular distribution, consistent with a large antibody-drug conjugate that remains primarily in the vascular space. |
| Bioavailability | Bioavailability is 100% for the intravenous route. No oral formulation exists; the drug is administered only as an intravenous infusion. |
| Onset of Action | Clinical response (e.g., tumor reduction) is typically observed after 2–3 cycles (6–9 weeks) of treatment. The onset is not immediate and requires multiple doses to achieve maximal therapeutic effect. No data for immediate clinical effect. |
| Duration of Action | The duration of clinical effect is not well-defined but is expected to persist for weeks to months after the last dose, corresponding to the persistence of the drug in plasma. The median duration of response in clinical trials was approximately 9 months for patients with relapsed/refractory diffuse large B-cell lymphoma. |
| Molecular Weight | 152000 |
1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended for elderly patients; monitor for increased toxicity, particularly infections and myelosuppression. |
| 1st trimester | Avoid. No human data; based on mechanism of action, may cause fetal harm. Animal studies show embryo-fetal toxicity. |
| 2nd trimester | Avoid. Polatuzumab vedotin is an antibody-drug conjugate with genotoxic maytansinoid; exposure during organogenesis and later gestation is expected to cause fetal harm. |
| 3rd trimester | Avoid. May cause fetal harm, particularly during late gestation due to potential for bleeding or other toxicities. |
Clinical note
Comprehensive clinical and safety monograph for POLIVY (POLIVY).
| Placental transfer | Expected to cross placenta due to low molecular weight (approximately 152 kDa for intact ADC, but small molecule component <1 kDa). Human data lacking; animal studies demonstrate transfer. |
| Breastfeeding | No human data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for at least 2 months after the last dose. |
| Lactation Rating | L5 |
| Teratogenic Risk | Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant women. There are no adequate and well-controlled studies in pregnant women. Verifies embryolethal and teratogenic effects in animal studies. The drug should be avoided during pregnancy, and women of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose. |
| Fetal Monitoring | Monitor pregnant women for fetal growth and development with serial ultrasound assessments. Given the potential for myelosuppression, monitor complete blood counts (CBC) regularly. Monitor for peripheral neuropathy and infections. Embryo-fetal toxicity monitoring is recommended if inadvertently exposed during pregnancy. |
| Fertility Effects | Based on animal studies, POLIVY may impair fertility in males and females. In female rats, decreased fertility and increased pre-implantation loss were observed. In male rats, testicular toxicity and impaired fertility were noted. Human data are lacking. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Concurrent use with strong CYP3A4 inducers or inhibitors (due to potential for altered exposure)Hypersensitivity to polatuzumab vedotin or any excipients
| Precautions | Peripheral neuropathy: Monitor for new or worsening neuropathy; may require dose modification or discontinuation., Infusion-related reactions: Premedicate with antihistamines and antipyretics; monitor during infusion., Myelosuppression: Neutropenia, thrombocytopenia, and anemia; monitor blood counts regularly., Infections: Increased risk of serious infections, including opportunistic infections., Hepatotoxicity: Elevations of liver enzymes; monitor liver function., Pneumonitis: Interstitial lung disease; monitor for pulmonary symptoms., Tumor lysis syndrome: Monitor patients at risk and manage accordingly., Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception. |
| Food/Dietary | No specific food interactions have been reported. Maintain adequate hydration. Avoid grapefruit or grapefruit juice if also taking certain CYP3A4 substrates, but no direct interaction with POLIVY. |
| Clinical Pearls | POLIVY (polatuzumab vedotin-piiq) is an antibody-drug conjugate targeting CD79b, used in combination with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Monitor for infusion-related reactions, peripheral neuropathy, and myelosuppression. Pre-medicate with antihistamines and antipyretics. Avoid in patients with moderate to severe hepatic impairment. |
| Patient Advice | This drug is given as an intravenous infusion; you may experience allergic reactions during or after infusion. · Report any numbness, tingling, or weakness in your hands or feet immediately. · You will have regular blood tests to monitor your blood cell counts and liver function. · Use effective contraception during treatment and for at least 3 months after the last dose. · Do not receive live vaccines while on this medication. |
Loading safety data…